RC1416 Placebo
Phase 2
RC1416 Placebo is one of 5 therapeutic programs targeting Chronic Obstructive Pulmonary Disease (COPD). It is currently in Phase 2.
1
Indications
1
Total Trials
1
Active Trials
4
Competitors
Pipeline
Status by Indication[2][1]
Indication
Competition
Competitive Landscape
7 competitors in Chronic Obstructive Pulmonary Disease (COPD)
#DrugCompanyPhaseTrials
1Tezspire
AstraZenecaPhase 3
RC1416
NNanjing RegeneCore Biotech Co., Ltd.
Phase 2
Trimethoprim-Sulfamethoxazole
AstellasPreclinical
RC1416 Placebo
NNanjing RegeneCore Biotech Co., Ltd.
Phase 2
KIT2014
KKither Biotech Srl
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]Open Targets Platform — Drug–disease associations for RC1416 Placebo. EMBL-EBI & Wellcome Sanger Institute.
- [3]
Details
Drug Info
Quick Facts
- Highest Phase
- Phase 2[1]